These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 17003315)

  • 1. Gut hormones and related concepts.
    Bloomgarden ZT
    Diabetes Care; 2006 Oct; 29(10):2319-24. PubMed ID: 17003315
    [No Abstract]   [Full Text] [Related]  

  • 2. Emerging treatments for patients with type 2 diabetes.
    Haines ST
    Diabetes Educ; 2007; 33 Suppl 5():105S-10S. PubMed ID: 17548897
    [No Abstract]   [Full Text] [Related]  

  • 3. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
    Drucker DJ; Nauck MA
    Lancet; 2006 Nov; 368(9548):1696-705. PubMed ID: 17098089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adapting the GLP-1-signaling system to the treatment of type 2 diabetes.
    Salvatore T; Carbonara O; Cozzolino D; Torella R; Sasso FC
    Curr Diabetes Rev; 2007 Feb; 3(1):15-23. PubMed ID: 18220652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.
    Amori RE; Lau J; Pittas AG
    JAMA; 2007 Jul; 298(2):194-206. PubMed ID: 17622601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors.
    Holst JJ; Deacon CF
    Diabetologia; 2005 Apr; 48(4):612-5. PubMed ID: 15759106
    [No Abstract]   [Full Text] [Related]  

  • 7. Glucagon-like peptide 1 and gastric inhibitory polypeptide: potential applications in type 2 diabetes mellitus.
    Meier JJ; Gallwitz B; Nauck MA
    BioDrugs; 2003; 17(2):93-102. PubMed ID: 12641488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1.
    Nauck MA; El-Ouaghlidi A
    Diabetologia; 2005 Apr; 48(4):608-11. PubMed ID: 15761719
    [No Abstract]   [Full Text] [Related]  

  • 9. What mediates the benefits associated with dipeptidyl peptidase-IV inhibition?
    Ahrén B
    Diabetologia; 2005 Apr; 48(4):605-7. PubMed ID: 15770467
    [No Abstract]   [Full Text] [Related]  

  • 10. [Incretin enhancers, incretin mimetics: from therapeutic concept to clinical application].
    Winkler G
    Orv Hetil; 2007 Apr; 148(13):579-87. PubMed ID: 17383951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New diabetes drugs target gut hormones.
    Kuehn BM
    JAMA; 2006 Jul; 296(4):380-1. PubMed ID: 16868285
    [No Abstract]   [Full Text] [Related]  

  • 12. Application of incretin mimetics and dipeptidyl peptidase IV inhibitors in managing type 2 diabetes mellitus.
    Boyle PJ; Freeman JS
    J Am Osteopath Assoc; 2007 May; 107 Suppl():S10-6. PubMed ID: 17724013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utilizing the GLP-1 signaling system to treat diabetes: sorting through the pharmacologic approaches.
    D'Alessio DA; Vahl TP
    Curr Diab Rep; 2005 Oct; 5(5):346-52. PubMed ID: 16188169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus.
    Siddiqui NI
    Mymensingh Med J; 2009 Jan; 18(1):113-24. PubMed ID: 19182763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes.
    Green BD; Flatt PR; Bailey CJ
    Diab Vasc Dis Res; 2006 Dec; 3(3):159-65. PubMed ID: 17160910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incretin hormone mimetics and analogues in diabetes therapeutics.
    Green BD; Flatt PR
    Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):497-516. PubMed ID: 18054732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The physiology of incretin hormones and the basis for DPP-4 inhibitors.
    McKennon SA; Campbell RK
    Diabetes Educ; 2007; 33(1):55-6, 60-2, 65-6. PubMed ID: 17272793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The incretin effect: a new therapeutic target in type 2 diabetes].
    Féry F
    Rev Med Brux; 2007 Sep; 28(4):329-35. PubMed ID: 17958029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incretins: what does the future hold?
    Edelman SV
    Diabetes Technol Ther; 2005 Oct; 7(5):809-12. PubMed ID: 16241889
    [No Abstract]   [Full Text] [Related]  

  • 20. [Two breakthroughs in the treatment of type 2 diabetes. Both the receptor agonist and enzyme inhibitors now available in the clinic].
    Ahrén B
    Lakartidningen; 2007 Dec; 104(49-50):3763-4. PubMed ID: 18214322
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.